EUVIMEDEUVIMED entdecken
Crossref

Oncolytic Virus Therapy In Cancer Research

Yuseph Khan, Avrina Kartika Ririe, Deydie Salazar, Jeyatheepan Jeyaretnam

International Journal of Drug Delivery Technology · 25.05.2026 · 16 (36s)

DOI: 10.25258/ijddt.16.36s.58 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, erschienen am 25.05.2026. Verfasst von Yuseph Khan und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Oncolytic virus therapy represents a novel approach to cancer treatment, utilizing genetically modified or naturally occurring viruses to selectively infect and destroy cancer cells. The therapy not only targets tumor cells but also stimulates the immune system to enhance anti-tumor responses. This study aims to evaluate the efficacy and safety of oncolytic virus therapy in reducing tumor size and activating the immune response in cancer patients.

Objective

The primary objective of this study is to assess the impact of oncolytic virus therapy on tumor regression, immune cell activation, and overall survival outcomes in cancer patients. Secondary objectives include evaluating the reliability of immune response measurements using scales such as Cronbach's Alpha and assessing the normality of the data on tumor size pre-and post-treatment.

Methods

A randomized controlled trial (RCT) was conducted with cancer patients diagnosed with advanced or metastatic cancers, such as melanoma and glioblastoma. Patients were randomly assigned to receive either oncolytic virus therapy or conventional treatments (chemotherapy or radiation). Data was collected at multiple time points to monitor tumor size changes through CT scans and MRIs, as well as immune response using blood biomarkers (e.g., T-cells, NK cells). Shapiro-Wilk tests were performed to assess the normality of tumor size data, while Cronbach's Alpha was used to evaluate the internal consistency of the immune response scale.

Results

The Shapiro-Wilk test indicated that the data for tumor size pre- and post-treatment were normally distributed (p > 0.05), allowing for the use of parametric statistical methods. The Cronbach's Alpha for the immune response scale was 0.957, indicating excellent internal consistency and reliability. The histograms and boxplots of tumor size distributions and immune response data showed normality and consistent responses, respectively, further supporting the reliability of the findings.

Conclusion

Oncolytic virus therapy appears to be a promising alternative or complement to traditional cancer treatments, showing significant potential in inducing tumor regression and stimulating the immune system. The study's results suggest that the therapy is effective and reliable, particularly in terms of immune response measurement. Further research with larger sample sizes and longer follow-up periods is required to confirm these findings and explore the therapy's long-term benefits.

Zitieren

APA

Khan, Y., Ririe, A. K., Salazar, D., & Jeyaretnam, J. (2026). Oncolytic Virus Therapy In Cancer Research. International Journal of Drug Delivery Technology, 16(36s). https://doi.org/10.25258/ijddt.16.36s.58

Vancouver

Khan Y, Ririe AK, Salazar D, Jeyaretnam J. Oncolytic Virus Therapy In Cancer Research. International Journal of Drug Delivery Technology. 2026;16(36s). doi:10.25258/ijddt.16.36s.58

BibTeX
@article{Khan2026,
  author = {Khan, Yuseph and Ririe, Avrina Kartika and Salazar, Deydie and Jeyaretnam, Jeyatheepan},
  title = {Oncolytic Virus Therapy In Cancer Research},
  journal = {International Journal of Drug Delivery Technology},
  year = {2026},
  volume = {16},
  number = {36s},
  doi = {10.25258/ijddt.16.36s.58}
}
Kostenlos starten →